247 related articles for article (PubMed ID: 35434626)
1. Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors.
Kong J; Long YQ
RSC Med Chem; 2022 Mar; 13(3):246-257. PubMed ID: 35434626
[TBL] [Abstract][Full Text] [Related]
2. Strategies to overcome drug resistance using SHP2 inhibitors.
Liu M; Gao S; Elhassan RM; Hou X; Fang H
Acta Pharm Sin B; 2021 Dec; 11(12):3908-3924. PubMed ID: 35024315
[TBL] [Abstract][Full Text] [Related]
3. Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies.
Song Z; Wang M; Ge Y; Chen XP; Xu Z; Sun Y; Xiong XF
Acta Pharm Sin B; 2021 Jan; 11(1):13-29. PubMed ID: 33532178
[TBL] [Abstract][Full Text] [Related]
4. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
5. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
6. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
7. Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials.
Song Y; Zhao M; Zhang H; Yu B
Pharmacol Ther; 2022 Feb; 230():107966. PubMed ID: 34403682
[TBL] [Abstract][Full Text] [Related]
8. Targeting SHP2 phosphatase in hematological malignancies.
Kanumuri R; Kumar Pasupuleti S; Burns SS; Ramdas B; Kapur R
Expert Opin Ther Targets; 2022 Apr; 26(4):319-332. PubMed ID: 35503226
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches.
Tojjari A; Saeed A; Sadeghipour A; Kurzrock R; Cavalcante L
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001644
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive review of SHP2 and its role in cancer.
Asmamaw MD; Shi XJ; Zhang LR; Liu HM
Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
[TBL] [Abstract][Full Text] [Related]
14. Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors.
Lambert LJ; Romero C; Sheffler DJ; Celeridad M; Cosford NDP; Tautz L
J Vis Exp; 2020 Jul; (161):. PubMed ID: 32744526
[TBL] [Abstract][Full Text] [Related]
15. Exploring the Allosteric Mechanism of Src Homology-2 Domain-Containing Protein Tyrosine Phosphatase 2 (SHP2) by Molecular Dynamics Simulations.
Wang Q; Zhao WC; Fu XQ; Zheng QC
Front Chem; 2020; 8():597495. PubMed ID: 33330386
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
17. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
Wu J; Zhang H; Zhao G; Wang R
Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
[TBL] [Abstract][Full Text] [Related]
18. A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors.
Song Y; Zhao M; Wu Y; Yu B; Liu HM
Acta Pharm Sin B; 2021 Mar; 11(3):750-762. PubMed ID: 33777680
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors.
Tang K; Zhao M; Wu YH; Wu Q; Wang S; Dong Y; Yu B; Song Y; Liu HM
Eur J Med Chem; 2022 Feb; 230():114106. PubMed ID: 35063735
[TBL] [Abstract][Full Text] [Related]
20. Development and structure-activity relationship study of SHP2 inhibitor containing 3,4,6-trihydroxy-5-oxo-5H-benzo[7]annulene.
Kim B; Jo S; Park SB; Chae CH; Lee K; Koh B; Shin I
Bioorg Med Chem Lett; 2020 Jan; 30(1):126756. PubMed ID: 31784318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
